Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.

CONCLUSION: AMG416 was well tolerated and appears to be an effective agent for the treatment of SHPT in patients on hemodialysis.
PMID: 26684933 [PubMed - as supplied by publisher]

Source: American Journal of Nephrology - December 19, 2015 Category: Urology & Nephrology Authors: Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, Spiegel DM, Walsh L, Mix TC, Kewalramani R Tags: Am J Nephrol Source Type: research